NZ724395A - Anti-pdgf-c antibodies - Google Patents

Anti-pdgf-c antibodies

Info

Publication number
NZ724395A
NZ724395A NZ724395A NZ72439513A NZ724395A NZ 724395 A NZ724395 A NZ 724395A NZ 724395 A NZ724395 A NZ 724395A NZ 72439513 A NZ72439513 A NZ 72439513A NZ 724395 A NZ724395 A NZ 724395A
Authority
NZ
New Zealand
Prior art keywords
pdgf
antibodies
inhibiting
binding
pdgfrα
Prior art date
Application number
NZ724395A
Other languages
English (en)
Inventor
Richard Zwaal
Claudia Fromond
Sofie Notebaert
Hoa Thu Ngo
Original Assignee
Thrombogenics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombogenics Nv filed Critical Thrombogenics Nv
Publication of NZ724395A publication Critical patent/NZ724395A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ724395A 2012-04-24 2013-04-24 Anti-pdgf-c antibodies NZ724395A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637372P 2012-04-24 2012-04-24
EP12165314 2012-04-24
US201261727231P 2012-11-16 2012-11-16
EP12192943 2012-11-16
NZ700274A NZ700274A (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Publications (1)

Publication Number Publication Date
NZ724395A true NZ724395A (en) 2018-03-23

Family

ID=49482233

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ724395A NZ724395A (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies
NZ700274A NZ700274A (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ700274A NZ700274A (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Country Status (13)

Country Link
US (1) US9884910B2 (enExample)
EP (1) EP2841454A1 (enExample)
JP (1) JP2015515487A (enExample)
KR (1) KR20150005631A (enExample)
CN (1) CN104321343A (enExample)
AU (1) AU2013254690B2 (enExample)
BR (1) BR112014025560A2 (enExample)
CA (1) CA2871528A1 (enExample)
IN (1) IN2014DN09717A (enExample)
MX (1) MX2014012843A (enExample)
NZ (2) NZ724395A (enExample)
RU (1) RU2014140116A (enExample)
WO (1) WO2013160359A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013254690B2 (en) 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies
EP3373967B9 (en) * 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
WO2018005904A2 (en) * 2016-07-01 2018-01-04 Ludwig Institute For Cancer Research Ltd Methods and compositions for pdgf-cc inhibition
KR101943083B1 (ko) * 2017-03-30 2019-01-29 (주)케어젠 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도
KR101943081B1 (ko) 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
JP2021505554A (ja) * 2017-12-04 2021-02-18 ラボラトリオス・サルバト・ソシエダッド・アノニマＬａｂｏｒａｔｏｒｉｏｓ Ｓａｌｖａｔ， Ｓ．Ａ． 眼の後部の疾患を治療するためのドベシル酸を含む眼科用局所組成物
KR102726837B1 (ko) * 2021-09-29 2024-11-07 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
WO2025038442A1 (en) * 2023-08-11 2025-02-20 Invetx, Inc. Anti-il-5 antibodies and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1991019515A1 (en) 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
WO1999047677A2 (en) 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologous to vegf and bmp1
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
CN1330664A (zh) 1998-09-30 2002-01-09 路德维格癌症研究所 血小板衍生生长因子c、其编码dna及其应用
WO2000034474A2 (en) 1998-12-07 2000-06-15 Zymogenetics, Inc. Growth factor homolog zvegf3
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
WO2001028586A1 (en) 1999-10-21 2001-04-26 Zymogenetics, Inc. Method of treating fibrosis
EP1267627A1 (en) * 2000-03-28 2003-01-02 Ludwig Institute For Cancer Research Non-human transgenic animals expressing platelet-derived growth factor c (pdgf-c) and uses thereof
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
DE602004021395D1 (de) 2003-07-25 2009-07-16 Zymogenetics Inc Verfahren zur behandlung von hepatozellulärem karzinom
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
AU2007240429A1 (en) * 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Ltd Methods and compositions for modulation of blood-neural barrier
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
AU2013254690B2 (en) 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies

Also Published As

Publication number Publication date
CN104321343A (zh) 2015-01-28
AU2013254690A1 (en) 2014-11-06
EP2841454A1 (en) 2015-03-04
US20150232546A1 (en) 2015-08-20
NZ700274A (en) 2016-10-28
US9884910B2 (en) 2018-02-06
WO2013160359A1 (en) 2013-10-31
RU2014140116A (ru) 2016-06-10
AU2013254690B2 (en) 2017-12-07
JP2015515487A (ja) 2015-05-28
IN2014DN09717A (enExample) 2015-07-31
MX2014012843A (es) 2017-01-23
CA2871528A1 (en) 2013-10-31
BR112014025560A2 (pt) 2017-07-04
KR20150005631A (ko) 2015-01-14

Similar Documents

Publication Publication Date Title
TN2015000396A1 (en) Antibody drug conjugates
NZ700274A (en) Anti-pdgf-c antibodies
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
IN2014KN00920A (enExample)
PH12017500890A1 (en) Antibody drug conjugates
WO2014163714A3 (en) Antibody drug conjugates
IN2014KN00848A (enExample)
EP3702372A3 (en) Anti-cd40 human antibodies
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
EA201791485A1 (ru) Анти-cd47-антитела и их применения
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
MX2014009751A (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
WO2012078688A3 (en) Humanized antibodies to liv-1 and use of same to treat cancer
PH12017500864A1 (en) Anti-notch1 antibodies
IN2014DN05885A (enExample)
MX368067B (es) Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo).
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2017002862A (es) Nuevos anticuerpos anti-mfi2 y metodos de uso.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
HK1196831A (en) Lsr antibodies, and uses thereof for treatment of cancer
HK1196856A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment